| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥1.0B | ¥5.6B | -81.4% |
| Operating Income | ¥-33.4B | ¥-28.4B | -17.5% |
| Profit Before Tax | ¥-21.3B | ¥-40.6B | +47.6% |
| Net Income | ¥-22.3B | ¥-42.3B | +47.3% |
| ROE | -45.5% | -202.8% | - |
FY2025 consolidated results: Revenue ¥0.1B (YoY -81.4%), Operating Loss ¥-3.3B (YoY -17.5% deterioration), Ordinary Loss ¥-2.4B (YoY +9.1% improvement), Net Loss ¥-2.2B (YoY +47.3% improvement). The period was characterized by substantial revenue contraction from ¥5.6B to ¥0.1B, while continuing heavy R&D investment of ¥2.0B (1946.2% of revenue). Despite widening operating losses, ordinary and net losses improved due to significant financial income of ¥1.4B. Equity financing activities generated ¥6.3B in financing cash flows, increasing cash and equivalents to ¥5.7B from ¥3.7B YoY. The company successfully raised ¥5.0B through new share issuances and warrant exercises, improving equity ratio from 14.5% to 28.7%. Gross profit turned negative at ¥-0.1B (margin -109.6%) as cost of sales ¥0.2B exceeded revenue. Basic EPS improved to ¥-20.59 from ¥-47.86, reflecting reduced net losses despite increased share count. The business remains pre-commercial with research development as core investment priority, funding operating activities through external capital rather than operational cash generation.
Revenue declined dramatically by 81.4% YoY to ¥0.1B from ¥5.6B, indicating loss of significant revenue streams during the period. Cost of sales increased to ¥0.2B from ¥0.1B despite lower revenue, resulting in negative gross profit of ¥-0.1B versus positive ¥0.4B prior year, representing gross margin deterioration of approximately 186 percentage points. This structural deterioration in gross profitability reflects fundamental business model challenges in the transition period.
SG&A expenses decreased 8.0% to ¥1.3B from ¥1.4B, showing modest cost control. However, R&D expenses increased 3.3% to ¥2.0B from ¥2.0B, maintaining high investment intensity. Combined operating expenses of ¥3.3B against minimal revenue drove operating loss to ¥-3.3B, deteriorating 17.5% from ¥-2.8B prior year. The operating margin reached -3211.5% versus -507.7% prior period.
At the ordinary income level, substantial improvement occurred due to financial income of ¥1.4B (up from ¥0.4B) and sharply reduced financial costs of ¥0.2B (down from ¥1.6B). This ¥2.8B swing in net financial items offset operating deterioration, improving ordinary loss to ¥-2.4B from ¥-2.6B (+9.1%). The financial income included investment securities gains and fair value adjustments on financial assets, representing non-recurring factors that may not persist.
Net income improved 47.3% to ¥-2.2B from ¥-4.2B, benefiting from lower income tax expense of ¥0.1B versus ¥0.2B prior year. The gap between ordinary loss (¥-2.4B) and net loss (¥-2.2B) remained minimal at approximately 6%, indicating limited extraordinary items below the ordinary income line.
This represents a revenue down/profit up (on ordinary and net income basis) pattern, driven by extraordinary financial gains offsetting fundamental operating deterioration. The improvement is financially engineered rather than operationally derived, warranting caution regarding sustainability.
[Profitability] ROE of -63.8% deteriorated from prior calculation base due to enlarged equity base through capital raises, though absolute net loss improved. Operating margin of -3211.5% reflects extreme mismatch between revenue scale and fixed cost base, worsening from -507.7% prior year as revenue contracted faster than costs adjusted. R&D intensity reached 1946.2% of revenue, indicating development-stage company economics. [Cash Quality] Cash and equivalents ¥5.7B provides 1.77x coverage of short-term debt of ¥0.5B and 3.0x coverage of current financial liabilities of ¥1.9B. Days Sales Outstanding calculated at approximately 827 days (¥0.2B receivables / ¥0.1B annual revenue × 365) indicates severely extended collection cycles or non-recurring receivable characteristics. Operating CF to net income ratio of 1.43x shows cash losses smaller than accounting losses, though both remain substantially negative. [Investment Efficiency] Asset turnover of 0.006x (¥0.1B revenue / ¥17.1B average assets) reflects minimal revenue generation from asset base. Intangible assets of ¥4.4B and financial assets of ¥5.2B comprise 56% of total assets, representing invested capital in development programs and strategic investments rather than revenue-generating operating assets. [Financial Health] Equity ratio improved to 28.7% from 14.5%, strengthening solvency position through ¥5.0B equity capital infusion. Debt-to-equity ratio of 0.42x (¥2.0B interest-bearing debt / ¥4.9B equity) appears moderate, though including Saisei Fund external investor interests of ¥4.7B in effective financial obligations raises total financial leverage substantially. Current ratio details incomplete but working capital position improved with cash buildup.
Operating cash outflow of ¥3.2B deteriorated 74.2% from ¥1.8B prior year, primarily driven by operating loss of ¥3.3B and working capital movements. The subtotal before working capital changes of ¥3.1B includes depreciation and amortization of ¥0.3B partially offsetting pre-tax loss of ¥2.1B. Working capital consumed additional cash with receivables increasing ¥0.03B and other current assets increasing ¥0.09B, while payables provided modest ¥0.06B inflow. Interest received of ¥0.03B and interest paid of ¥0.06B reflected net interest burden. Investing cash outflow of ¥1.1B comprised primarily investment securities purchases of ¥1.0B and tangible asset capex of ¥0.2B, with proceeds from investment sales contributing ¥0.03B. Financing activities generated strong ¥6.3B inflow, consisting of bond issuance proceeds of ¥1.6B (prior year), new share issuance proceeds of ¥3.1B from warrant exercises and ¥1.9B from regular capital raises, and Saisei Fund external investor contributions of ¥1.5B. Lease payment obligations of ¥0.1B were serviced. Free cash flow of ¥-4.3B (operating CF ¥-3.2B plus investing CF ¥-1.1B) demonstrates continued dependency on external financing. Cash position increased ¥2.0B net to ¥5.7B after FX impact of ¥-0.05B, providing runway extension from capital market activities. The positive financing CF of ¥6.3B exceeded combined operating and investing outflows of ¥4.3B by ¥2.0B, successfully replenishing liquidity reserves.
Operating loss of ¥3.3B compared to ordinary loss of ¥2.4B reflects net non-operating contribution of approximately ¥0.9B positive impact. This comprises financial income of ¥1.4B substantially exceeding financial costs of ¥0.2B, representing a ¥1.2B net financial gain, partially offset by equity method losses of ¥0.002B and other non-operating items of ¥0.06B net. Financial income at ¥1.4B represents 1357.7% of revenue, consisting primarily of fair value gains on financial assets and investment securities gains, indicating substantial dependency on non-operating sources. The ¥1.2B improvement in net financial items YoY (from ¥-1.2B to ¥1.2B) resulted from both increased financial income (¥1.4B vs ¥0.4B) and dramatically reduced financial costs (¥0.2B vs ¥1.6B), suggesting debt restructuring or fair value movements in derivative instruments. Operating cash outflow of ¥3.2B exceeds net income loss of ¥2.2B in absolute terms by ¥1.0B, indicating working capital consumption and timing differences that modestly pressure cash-based earnings quality. However, the relationship between accounting loss and cash loss remains reasonably aligned at 1.43x ratio. Accruals analysis shows receivables increased ¥0.05B while payables decreased ¥0.1B YoY, creating ¥0.15B working capital headwind. The substantial financial income should be viewed as non-recurring given its exceptional nature relative to operating scale, suggesting underlying earnings quality from operations remains challenged by ¥3.3B operating loss core reality.
R&D program failure or regulatory approval delays present the highest materiality risk, as the company invested ¥2.0B (19.2% of total assets) in R&D during the period with zero commercialized revenue generation. Clinical trial setbacks, regulatory rejections, or competitor advances could render invested capital unrecoverable and eliminate future revenue potential. The business model entirely depends on successful development pipeline outcomes over multi-year horizons.
Financial leverage and refinancing risk warrants close monitoring given debt-to-equity ratio of 0.42x excluding, but 1.38x including Saisei Fund external investor interests of ¥4.7B as quasi-debt obligations. Interest-bearing debt of ¥2.0B combined with operating cash burn of ¥3.2B annually creates refinancing needs within 1.9 years at current burn rate, absent additional capital raises. Bond maturity of ¥1.6B non-current and ¥0.5B current borrowings present near-term repayment obligations potentially requiring additional dilutive equity raises given negative operating cash flow.
Revenue concentration and customer dependency risk is evidenced by 81.4% revenue decline YoY from ¥5.6B to ¥0.1B, suggesting prior period revenue derived from single large contract or licensing arrangement that terminated or substantially reduced. With Days Sales Outstanding of 827 days and receivables of ¥0.2B against ¥0.1B annual revenue, significant collection risk exists on remaining outstanding amounts. The inability to replace lost revenue sources and extreme customer concentration creates business continuity uncertainty absent successful clinical program monetization.
[Industry Position] (Reference - Proprietary Analysis)
The company exhibits characteristics of early-stage biopharmaceutical development enterprises with pre-commercial operations and capital-intensive R&D profiles. ROE of -63.8% positions significantly below industry standards for development-stage biotechnology, though direct comparability is limited by exceptional equity base expansion and timing of capital raises. The equity ratio improvement to 28.7% moves toward more sustainable capitalization levels, though still below typical 40-50% ranges for established pharmaceutical operations. Operating margin of -3211.5% reflects development-stage economics where fixed R&D costs vastly exceed minimal revenue, a common but unsustainable intermediate state requiring successful commercialization transition. R&D intensity of 1946.2% of revenue far exceeds typical pharmaceutical industry ranges of 15-25% for commercial-stage companies, confirming pre-revenue development focus. The company's business model combines elements of regenerative medicine development with fund management operations (Saisei Fund), creating hybrid risk/return profiles. Industry benchmark comparison indicates the company operates in early clinical/pre-clinical phases with 3-7 year typical timelines to potential commercialization, requiring sustained external funding through multiple capital raise cycles. Financial structure shows improving but still elevated leverage relative to asset-light biotech peers, with debt serviceability entirely dependent on capital market access rather than operational cash generation.
(※ Industry: Biopharmaceutical Development, Comparison: Development-stage companies, Source: Proprietary analysis)
The FY2025 results reveal a company in fundamental business model transition, having lost primary revenue sources (81.4% decline) while maintaining full development-stage cost structure. The ¥5.0B equity capital raise successfully extended operational runway and improved equity ratio to 28.7% from critically low 14.5%, buying time for pipeline development programs to mature. However, structural challenges persist with negative gross margins of -109.6%, indicating revenue activities currently destroy value before operating expenses, and operating cash burn of ¥3.2B annually consuming approximately 56% of year-end cash position within one year absent additional funding.
Financial income of ¥1.4B (representing 1358% of revenue) provided critical ordinary income improvement of 9.1% YoY, but this non-recurring benefit from investment gains and fair value adjustments masks continued operating deterioration. The company's viability depends entirely on (1) successful clinical program advancement generating licensing revenues or milestones, (2) continued capital market access for refinancing ¥2.0B debt maturities and funding ¥3.2B annual operating burn, and (3) eventual revenue model reconstruction following revenue base collapse. Days Sales Outstanding of 827 days signals either exceptional receivable collection challenges or non-standard revenue recognition timing requiring clarification.
The investment proposition centers on binary R&D outcomes over 3-7 year horizons, with ¥4.4B intangible assets and ¥2.0B annual R&D spend representing accumulated bets on pipeline success. Positive indicators include improved capital structure post-raise, maintained R&D investment discipline, and financial asset base of ¥5.2B providing some value floor. Risk factors include extreme operating leverage, demonstrated revenue volatility, debt maturity schedule pressuring near-term refinancing needs, and potential dilution from anticipated future capital raises. The 47.3% net loss improvement YoY and reduced cash burn rate (if sustained) could indicate inflection toward more efficient operations, though visibility remains limited without segment-level disclosure or detailed pipeline guidance.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.